Aadi Bioscience Shares Are Trading Lower After the Company Announced an Analysis by the Independent Data Monitoring Committee Demonstrated That the Study Was Unlikely to Exceed an Efficacy Threshold Necessary to Support an Accelerated Approval. The...

Aadi生物科學公司宣佈獨立數據監測委員會的分析顯示該研究不太可能達到支持加速批准所需的療效門檻後，股票價格下跌。該公司正在評估可用的數據以進行未來決策。

Benzinga · 08/21 19:58

Aadi Bioscience Shares Are Trading Lower After the Company Announced an Analysis by the Independent Data Monitoring Committee Demonstrated That the Study Was Unlikely to Exceed an Efficacy Threshold Necessary to Support an Accelerated Approval. The Company Will Pause New Enrollment and Is Reducing Its Research & Development Workforce by 80%.

Aadi Bioscience股價下跌，因該公司宣佈由獨立數據監測委員會進行的分析顯示，該研究不太可能超過支持加速批准所需的療效閾值。公司將暫停新的招募，並將其研發人員規模減少80%。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。